Gene variations related to the hepatocellular carcinoma: Results from a field synopsis and Bayesian revaluation

• Published in: Gene Vol. 869; p. 147392
• Main Authors: Penha Mesquita, Abel, Victor Oliveira Monteiro, André, Luiz Araújo Bentes Leal, Alessandro, dos Santos Pessoa, Larissa, de Siqueira Amorim Júnior, José, Rogério Souza Monteiro, José, Andrade de Sousa, Aline, Fernando Pereira Vasconcelos, Daniel, Carolina Alves de Oliveira, Ana, Leão Pereira, Adenilson, Rodolfo Pereira da Silva, Felipe
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.06.2023
• Subjects: Bayes Theorem; Bayesian theory; Biomarkers; Carcinoma, Hepatocellular - genetics; genes; Genetic Predisposition to Disease; Hepatic cancer; hepatoma; Humans; interleukin-6; Liver neoplasms; Liver Neoplasms - genetics; meta-analysis; odds ratio; Polymorphism, Single Nucleotide; Polymorphisms; risk; Risk Factors; Hepatic cancer; HFE; I2; TNF; CCND1; HWE; CTLA4; IL12B; IL12A; KIF1B; Th1; HBV; Risk Factors; IL18; HCC; FPRP; IL-12; IL-6; IL-12RB1; miR; Biomarkers; HCV; CYP2E1; HLA; TP53; ABF; GSTP1; XPD; BFDP; IFN; mEH; STAT4; Liver neoplasms; MICA; IL18B; IL-6R; NQO1; OR; EGF; CI; Cox2; PRISMA; MTHFR; XRCC1; Polymorphisms; TM6SF2; MnSOD; MDM2; CYP1A1; PNPLA3; Fas; PO
• ISSN: 0378-1119; 1879-0038; 1879-0038
• DOI: 10.1016/j.gene.2023.147392

•The calculations showed specific SNPs as noteworthy for HCC risk.•The STAT4 and MDM2 genes have a central role in hepatocellular carcinoma.•The genes that were noteworthy are potential biomarkers for the disease. Hepatocellular carcinoma (HCC) is considered as the second cause of cancer-related deaths worldwide. Genetic variations are associated with HCC risk, an issue that has been the subject of several meta-analyses. However, meta-analyses have an important limitation on the likelihood of false positive data. Henceforth, this study aimed to assess the level of noteworthiness in the meta-analyses by means of a Bayesian approach. A systematic search was performed for meta-analyses with associations between gene polymorphisms and HCC. The calculations for the False-Positive Rate Probability (FPRP) and the Bayesian False Discovery Probability (BFDP) were performed to assess the noteworthiness with a statistical power of 1.2 and 1.5 of Odds Ratio at a prior probability of 10−3 and 10−5. The quality of studies was evaluated by the Venice criteria. As additional analyses, the gene-gene and protein–protein networks were designed for these genes and products. As results, we found 33 meta-analytic studies on 45 polymorphisms occurring in 35 genes. A total of 1,280 values for FPRP and BFDP were obtained. Seventy-five for FPRP (5.86%) and 95 for BFDP (14.79%) were noteworthy. In conclusion, the polymorphisms in CCND1, CTLA4, EGF, IL6, IL12A, KIF1B, MDM2, MICA, miR-499, MTHFR, PNPLA3, STAT4, TM6SF2, and XPD genes were considered as noteworthy biomarkers for HCC risk.